BUZZ-CervoMed tumbles after dementia drug fails to meet mid-stage trial goals

Reuters12-10

** Shares of drug developer CervoMed fall 71.3% to $2.90 premarket

** Co says its drug, neflamapimod, did not meet the main and secondary goals in a mid-stage trial testing it as a treatment for dementia with Lewy bodies $(DLB)$

** DLB is a form of dementia caused by the accumulation of protein deposits called Lewy bodies in the brain's nerve cells

** CRVO says the drug, neflamapimod, did not achieve the trial's main goal of significantly reducing symptoms of dementia

** CervoMed CEO John Alam says the company is pausing all preparations for its previously planned late-stage trial for the treatment until full analysis of the trial data is complete

** Up to last close, stock up 34.3% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment